Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology industry, suggesting it is at a turning point for profit improvement and has high allocation value [3][4]. Core Insights - The pharmaceutical sector is showing signs of recovery after three years of declining profitability, with a notable increase in net profit margin by 0.3% in Q1 2025 compared to the previous year [3][5]. - Key sub-sectors such as CXO, innovative drugs, biological products, private hospitals, and medical consumables have demonstrated strong performance in Q1 2025, with several leading companies exceeding expectations [3][4]. - The report recommends focusing on sub-sectors and companies with clear upward trends in performance, including innovative drugs and CXO services [3][4]. Overall Performance of the Sector - In 2024, 473 A-share pharmaceutical companies achieved total revenue of 24,588 billion yuan, a year-on-year decrease of 0.9%, and a net profit of 1,412 billion yuan, down 12.1% [3][5]. - For Q1 2025, the sector reported revenue of 6,104 billion yuan, a decline of 4.2% year-on-year, with net profit at 487 billion yuan, down 8.7% [3][5]. Sub-sector Performance - The CXO sector has shown a turnaround since Q4 2024, with Q1 2025 revenue of 225 billion yuan, reflecting an 11.6% year-on-year increase, and net profit of 50 billion yuan, up 72.8% [3][23]. - The innovative drug sector continues to grow rapidly, with leading companies like Heng Rui Medicine and Bai Jie Shen Zhou performing above expectations [3][18]. - The hospital sector is beginning to show signs of recovery, with Q1 2025 revenue of 144 billion yuan, a year-on-year increase of 4.9%, and net profit of 11 billion yuan, up 19.2% [3][28]. Investment Analysis - The report emphasizes the importance of investing in sectors and companies that are showing clear signs of upward trends, particularly in innovative drugs and CXO services [3][4]. - Specific companies recommended for investment include Heng Rui Medicine, Bai Jie Shen Zhou, and Wu Xi AppTec in the innovative drug and CXO sectors [3][4].

Core Viewpoint - The Chinese traditional medicine industry is experiencing collective anxiety due to insufficient effective demand, accelerated industry transformation, policy changes, and intense market competition [1] Industry Performance Overview - The performance of traditional Chinese medicine companies in 2024 and the first quarter of 2025 shows a diverging trend, with some companies achieving stable growth through brand advantages and product innovation, while others face revenue declines and profit pressures [1][3] - In 2024, Baiyunshan led the industry with a revenue of 749.93 billion yuan, but experienced a slight decline of 0.69% year-on-year, indicating growth challenges for traditional giants [3][6] - Yunnan Baiyao and China Resources Sanjiu followed with revenues of 400.33 billion yuan and 276.17 billion yuan, reflecting year-on-year growth rates of 2.36% and 11.63%, respectively [3][6] - In the first quarter of 2025, leading companies continued to show growth, while trailing companies remained under pressure [1][6] Profitability Insights - Yunnan Baiyao reported a net profit of 47.67 billion yuan in 2024, maintaining a growth rate of 15.63%, while Pizhou's net profit reached 29.96 billion yuan, aligning with its revenue growth [6] - Daren Tang emerged as a "profit dark horse" with a net profit increase of 128.68% year-on-year, while Dong'e Ejiao's net profit grew by 25.57% due to product price increases and channel optimization [6][1] R&D and Sales Expenses - In 2024, the highest R&D investment was from Tianshili, amounting to 1.039 billion yuan, representing 12.23% of its revenue [6][7] - Sales expenses were highest for China Resources Sanjiu at 72.20 billion yuan, followed by Baiyunshan at 56.20 billion yuan [7] - The overall R&D investment among the top 20 companies indicates a need for improvement, especially in innovative drug development and modern Chinese medicine technology applications [7] Market Challenges and Strategic Responses - The unique product strategy, once a cash cow for many companies, is now facing challenges due to adjustments in medical insurance directories and expanded centralized procurement [9][10] - Companies like Step Long Pharmaceutical have reported significant losses due to high sales expenses and declining core product revenues [1][6] - The industry is witnessing a trend where companies are either "slimming down" by divesting non-core assets or "bulking up" through mergers and acquisitions to strengthen their market position [14][15] Future Outlook - The ongoing centralized procurement and market dynamics necessitate that companies balance pricing and market share while building brand moats [12][14] - Companies with unique proprietary formulas, such as Pizhou and Yunnan Baiyao, are better positioned to withstand market fluctuations compared to those reliant on single products without strong patent protection [11][12]

| 本次解质 | | | | | | 已质押股份情况 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 本次解质押 | | | | | 占 | | | | | 押及再质 | 公 | 情况 | | 占其所 | | | | | | 持股数量 持股比 | 股东名 | | 及再质押前 | | | 司总 | | 已质押股 | | 占已 | 份 | | 占未 | | | | | | | 押后质押 | | | | 持股 | | | | | | 未质押股份 | 份 | | | | | | | | | 例 | 称 （股） | | 质押股份数 | | | 股本 | 限售和 | | | 质押 | 冻 | | 质押 | | | | | | | 股份数量 | | | | 比 | | | | | | 限售和冻结 | 例 | | | | | | | | | 量（股） | | | | | 比例 | 结、标记数 | | 股 | | 股份 | 份 | | | | | | | | | （股） | | | | | 数量（股） | | | | | | | | | | | 量 ...

股票代码：000538 股票简称：云南白药 公告编号：2025-19 年 5 月 12 日解除质押，详见"一、本次股份解除质押基本情况"。 质押股份是否负担重大资产重组等业绩补偿义务：否。 云南白药集团股份有限公司 关于股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）于 近日接到公司股东新华都实业集团股份有限公司（以下简称"新华都"） 的通知，获悉新华都将其持有的公司部分股份办理了解除质押及再质押。 具体情况如下： | 股东名称 | 是否为控股股 东或第一大股 | 本次解除质押 /冻结/拍卖等 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人/申请 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一致行 动人 | 股份数量 | 比例 | 比例 | | | 人等 | | 新华都实业 集团股份有 | 否 | 290,514,000 | 66.67% | 16.28% | 20 ...

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the past 30 days include Huaming Equipment, Changshu Bank, Guangdian Yuntong, Yunnan Baiyao, and BYD. In the last five days, the most visited companies were Mankalon, Zhou Dasheng, Stable Medical, Zhujiang Beer, and Shenghe Resources. Among the top twenty companies in the past 30 days, 11 companies had 10 or more rating agencies, including BYD, Huali Group, Weixing New Materials, Changshu Bank, and Weixing Co., Ltd. [2][11][12] - Companies such as BYD, Huali Group, Changshu Bank, Weixing Co., Ltd., Weichai Power, Yunnan Baiyao, Tuobang Co., Ltd., Huaming Equipment, and Zhongji United are expected to see significant growth in net profit attributable to shareholders in 2024 compared to 2023 [2][11][12]. Group 2: Shareholder Increase Activities - From May 5 to May 9, 2025, a total of 13 companies announced significant shareholder increases, with three companies having 10 or more rating agencies. The companies with an average proposed increase amount exceeding 1% of the latest market value include *ST Gengxing, Hainan Development, China Railway Industry, Huamao Technology, and Linglong Tire [3][14][15]. - From January 1 to May 11, 2025, 297 companies announced significant shareholder increases, with 203 having 10 or more rating agencies. Among these, 15 companies had an average proposed increase amount exceeding 1% of the latest market value, including Xinjie Energy, Sailun Tire, Rongsheng Petrochemical, Wanrun Co., Ltd., CNOOC Engineering, and Xin Fengming [5][16][17]. Group 3: Company Buyback Activities - From May 5 to May 9, 2025, a total of 312 companies announced buyback progress, with 84 companies having 10 or more rating agencies. Companies expected to have a buyback amount exceeding 1% of the market value on the announcement date include Pingmei Co., Ltd., Huafa Co., Ltd., Changhong Meiling, XGIMI Technology, and Xugong Machinery [4][19][20]. - From January 1 to May 11, 2025, 1,456 companies announced buyback progress, with 297 having 10 or more rating agencies. Among these, 82 companies had a buyback amount exceeding 1% of the market value on the announcement date, including Changhong Meiling, Qianwei Central Kitchen, Baolong Technology, Shantui Co., Ltd., Wanrun Co., Ltd., Midea Group, BOE A, and Goldwind Technology [6][22][23].

为进一步加强与投资者的互动交流，云南白药集团股份有限公司（以下简 称"公司"）将参加由云南证监局指导，云南省上市公司协会与深圳市全景网 络有限公司联合举办的"2024 年度云南辖区上市公司投资者网上集体接待日"， 现将相关事项公告如下： 股票代码：000538 股票简称：云南白药 公告编号：2025-18 云南白药集团股份有限公司 关于参加云南辖区上市公司 2024 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 16 日（周五）16:00-17:00。届时 公司部分高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况 和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与！ 特此公告 云南白药集团股份有限公司 董 事 会 2025 年 5 月 12 日 1 / 1 ...

Group 1 - The Shanghai Composite Index opened high and the CSI 300 Pharmaceutical and Biotechnology Index reported 7624.71 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.46% in the past month, 3.56% in the past three months, and 2.43% year-to-date [1] - The index is designed to reflect the overall performance of different industry companies within the CSI 300 Index, categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.5%), WuXi AppTec (15.98%), Pian Zai Huang (6.77%), Yunnan Baiyao (5.51%), Kelun Pharmaceutical (4.73%), New Horizon (3.69%), East China Pharmaceutical (3.68%), Shanghai Raist (3.39%), Changchun High-tech (3.33%), and Fosun Pharma (3.23%) [1] - The market segment of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.75% and the Shenzhen Stock Exchange accounts for 36.25% [2] - In terms of industry composition, chemical drugs account for 43.27%, pharmaceutical and biotechnology services for 21.11%, traditional Chinese medicine for 19.35%, and biological drugs for 16.27% [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are fixed until the next scheduled adjustment unless a temporary adjustment is required [2] - Special events affecting sample companies may lead to changes in industry classification, and companies that are delisted will be removed from the index [2]

Core Insights - In 2024, China's total retail sales of consumer goods reached 48.79 trillion yuan, growing by 3.5%, marking the first time it fell below the GDP growth rate of 5% [1] - The fast-moving consumer goods (FMCG) industry is transitioning into a phase dominated by "stock competition," focusing on efficiency improvement, brand optimization, and structural adjustments [1] FMCG Company Performance - **Kang Shifu**: Achieved revenue of 806.51 billion yuan, a slight increase of 0.30%, with net profit rising by 19.80% to 37.34 billion yuan [2][6][8] - **Nongfu Spring**: Revenue of 428.96 billion yuan, up 0.50%, with net profit at 121.23 billion yuan, a marginal increase of 0.40% [2][6][9] - **Uni-President**: Revenue reached 303.32 billion yuan, a 6.09% increase, with net profit of 18.49 billion yuan, up 10.90% [2][6][10] - **China Foods**: Reported revenue of 214.92 billion yuan, a 0.20% increase, and net profit of 8.61 billion yuan, up 3.40% [2][6][11] - **Dongpeng Beverage**: Revenue surged to 158.39 billion yuan, a 40.63% increase, with net profit at 33.27 billion yuan, up 63.09% [2][6][12] - **Three Squirrels**: Revenue of 106.22 billion yuan, a significant increase of 49.30%, with net profit rising by 85.51% to 4.08 billion yuan [2][6][14] - **Liangpinpuzi**: Revenue decreased to 71.59 billion yuan, down 11.02%, with a net loss of 0.46 billion yuan [2][6][15] - **Zhi Zhi Food**: Revenue of 71.31 billion yuan, up 4.79%, with net profit of 8.49 billion yuan, up 5.82% [2][6][15] - **Tao Li Bread**: Revenue of 60.87 billion yuan, down 9.93%, with net profit of 5.22 billion yuan, down 9.05% [2][6][15] Industry Trends - The FMCG sector is experiencing a shift towards efficiency and brand optimization as the market matures, with companies adapting to changing consumer preferences and competitive pressures [1][16] - Companies like Dongpeng Beverage and Three Squirrels are successfully leveraging product innovation and market expansion to drive growth, while others like Liangpinpuzi face challenges due to strategic missteps [12][14][15] - The beverage segment, particularly tea drinks, is emerging as a key growth area for companies like Nongfu Spring, which is focusing on enhancing its product offerings and maintaining its market leadership [9][16] Dairy Industry Performance - **Yili**: Achieved revenue of 1157.80 billion yuan, a decline of 8.24%, with net profit of 84.53 billion yuan, down 18.94% [18][19] - **Mengniu**: Revenue fell to 886.75 billion yuan, down 10.09%, with a net profit of 1.05 billion yuan, a drastic drop of 97.83% [18][20] - **Bright Dairy**: Revenue of 242.78 billion yuan, down 8.33%, with net profit of 7.22 billion yuan, down 25.36% [18][21] - **Feihe**: Revenue increased to 207.50 billion yuan, up 6.00%, with net profit of 36.50 billion yuan, up 11.00% [18][22] - The dairy sector is facing significant challenges, with many companies reporting revenue and profit declines due to oversupply and weak consumer demand [22]

Investment Rating - The industry investment rating is "Positive" [1] Core Viewpoints - The second quarter is recommended for the traditional Chinese medicine sector, with expectations for a performance turning point despite significant pressure in the first quarter [3][10] - The traditional Chinese medicine sector is anticipated to see a recovery in performance due to improved inventory levels and profitability, alongside favorable conditions from U.S. tariff policies [5][21] Summary by Sections 1. Quarterly Report Overview - The first quarter faced substantial pressure, but nearly half of the companies (31) achieved positive growth in net profit attributable to shareholders after excluding non-recurring items, with 18 companies reporting revenue growth [13][14] - Companies such as Jia Ying Pharmaceutical and Te Yi Pharmaceutical reported significant revenue growth of 28.8% and 79.3%, respectively, driven by channel expansion and marketing reforms [14] 2. Core Indicator Tracking - Inventory levels have decreased, leading to sustained improvements in profitability [18] - The traditional Chinese medicine sector's valuation is currently below the average since 2021, indicating potential for recovery [24] 3. Investment Recommendations - Companies with strong brand power and potential for margin improvement are recommended for aggressive investment, including Dong E E Jiao, Tong Ren Tang, and Pian Zai Huang [10][18] - Defensive investments are suggested in stable dividend-paying assets such as Yunnan Baiyao and Ling Rui Pharmaceutical [10][18] - The sector's overall valuation is low, with a TTM price-to-earnings ratio of 27.00x as of May 9, 2025, which is below the average since 2021 [24]

Core Viewpoint - The article compares the financial performance and business strategies of two leading companies in the traditional Chinese medicine sector: Pian Zai Huang and Yunnan Baiyao, highlighting their strengths and weaknesses in profitability, business structure, cash flow, and shareholder returns [2][7]. Profitability - Pian Zai Huang reported a revenue of 3.142 billion yuan in Q1, a slight decrease of 0.92% year-on-year, but net profit increased by 2.59% to 1 billion yuan. The gross margin decreased from 47% to 45%, while sales expenses were cut by 38%, resulting in a net profit of 32 yuan per 100 yuan sold, an increase of 0.8 yuan from the previous year [2][5]. - Yunnan Baiyao achieved a revenue of 10.841 billion yuan, a minor increase of 0.62%, with net profit soaring by 13.67% to 1.935 billion yuan. The industrial gross margin reached 68.34%, with industrial revenue up by 7.63%. The company also reduced sales expenses by 13.23% and management expenses by 3.12%, while R&D expenses rose by 4.96% [2][4]. Business Structure - Pian Zai Huang's core business focuses on liver disease medication, facing significant cost pressures with the price of raw materials increasing by 154%. The company raised the price of its key product to 760 yuan per unit and expanded its distribution network, resulting in a 21% increase in hospital sales. Additionally, its cosmetics line generated 100 million yuan in revenue, a 41% increase year-on-year [3][4]. - Yunnan Baiyao's industrial segment generated 4.470 billion yuan in revenue, a 7.63% increase, while its commercial segment brought in 6.371 billion yuan but with a low gross margin of 6.21%. The company is also integrating AI technology into its operations for marketing and R&D [4][5]. Cash Flow and Risks - Pian Zai Huang reported a net cash inflow from operating activities of 916 million yuan, a 72.33% increase, attributed to strong cash collection and extended supplier payment terms. The company has sufficient inventory to last until 2030 [5]. - Yunnan Baiyao's operating cash flow was 714 million yuan, a 35.39% increase, but it faced high accounts receivable of 10.924 billion yuan, a 10.08% increase, indicating potential cash collection challenges [5]. Dividends and Valuation - Pian Zai Huang's diluted earnings per share were 1.66 yuan, with a dividend yield of less than 1%, indicating a conservative approach to shareholder returns [6]. - Yunnan Baiyao reported earnings per share of 1.08 yuan, with a dividend yield of around 4% and a high payout ratio of 90.09%, reflecting a more generous distribution to shareholders [6]. Conclusion - Pian Zai Huang relies on scarce raw materials, brand premium, and diversification into cosmetics to maintain its market value, but faces long-term innovation challenges due to low R&D spending [7]. - Yunnan Baiyao leverages its toothpaste and daily chemical products along with AI transformation to solidify its market leadership, but contends with low margins in its commercial segment and high accounts receivable [7].